Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Short Interest Update

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) was the recipient of a large decrease in short interest in September. As of September 30th, there was short interest totalling 27,400 shares, a decrease of 24.7% from the September 15th total of 36,400 shares. Based on an average trading volume of 129,700 shares, the days-to-cover ratio is presently 0.2 days. Approximately 2.1% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 16th.

Insider Transactions at Pieris Pharmaceuticals

In related news, major shareholder Adar1 Capital Management, Llc purchased 3,000 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The shares were bought at an average cost of $15.88 per share, with a total value of $47,640.00. Following the acquisition, the insider now owns 129,574 shares of the company’s stock, valued at $2,057,635.12. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 8.89% of the company’s stock.

Pieris Pharmaceuticals Price Performance

Shares of NASDAQ:PIRS traded down $0.02 during trading on Tuesday, hitting $16.25. 9,248 shares of the company were exchanged, compared to its average volume of 50,023. Pieris Pharmaceuticals has a 52-week low of $6.20 and a 52-week high of $23.20. The stock has a 50 day moving average of $16.89 and a 200 day moving average of $13.16. The company has a market cap of $21.45 million, a PE ratio of -1.36 and a beta of 0.67.

Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its earnings results on Wednesday, August 14th. The biotechnology company reported ($2.76) EPS for the quarter. Pieris Pharmaceuticals had a negative return on equity of 101.29% and a negative net margin of 39.71%.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.